Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

64.29 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 47,845
Open 64.29
Bid (Size) 65.23 (21)
Ask (Size) 65.27 (19)
Prev. Close 64.29
Today's Range 64.29 - 64.29
52wk Range 52.65 - 72.12
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Beat the Dow Jones With This Unstoppable Dividend Stock
This pharmaceutical company has outperformed the Dow Jones index over the last 10 years. 
Via The Motley Fool
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aiming to Capture Significant Market Share for Treatment and Prevention of COVID-19 Illness with Innovative Inhaled NanoAb
Via Investor Brand Network
Exposures COVID-19 Product Safety

Performance

YTD
-7.27%
-7.27%
1 Month
-9.32%
-9.32%
3 Month
+4.83%
+4.83%
6 Month
-2.43%
-2.43%
1 Year
+13.43%
+13.43%

More News

Read More
Danaher Shows Interest In Acquiring Catalent Valued At Significant Premium: Report
Via Benzinga
Is Gilead Sciences a Good Stock to Buy Now?
Via The Motley Fool
Top 5 Health Care Stocks That May Rally
Via Benzinga
AZN Stock Under Pressure
Via Talk Markets
The Top Healthcare Stocks to Buy With $100
Via The Motley Fool
Johnson & Johnson's Upcoming Lung Cancer Data Could Offer Another Blockbuster Opportunity, Says Analyst
Via Benzinga
TEZSPIRE® approved for self-administration in the US with a new pre-filled pen
From AstraZeneca
Via Business Wire
3 No-Brainer Dividend Stocks to Buy Hand Over Fist in 2023
Via The Motley Fool
These 2 Healthcare Stocks Have Doubled in 2023
Via MarketBeat
$1,000 Invested In 4 Of The 5 Vaccine Developers Back When WHO Declared COVID-19 An Emergency Yielded Returns
Via Benzinga
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Via MarketBeat
Exposures Product Safety
Could This Vaccine Become Sanofi's Latest Blockbuster?
Via The Motley Fool
Could This Be Novartis' Next Blockbuster Medicine?
Via The Motley Fool
7 Dividend Stocks to Buy for a Stable Income Stream
Via InvestorPlace
Mergers and Acquisitions in 2023 Off To A Strong Start
Via MarketBeat
Exposures Product Safety
Is Johnson & Johnson Still a Good Dividend Stock to Buy?
Via The Motley Fool
AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.
From AstraZeneca
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)
From Brodsky & Smith LLC
Via Globe NewsWire
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
Via Investor's Business Daily
AstraZeneca’s Next “Wonder Drug”
Via Talk Markets
Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials
Via FinancialNewsMedia
Exposures COVID-19 Product Safety
AbbVie Stock: Dividend King ABBV Overview
Via MarketBeat
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
From HUTCHMED (China) Limited
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.